Is Humana Stock a Good Investment in 2026? HUM Fundamentals Explained

Humana has told the market that 95% of its Medicare Advantage members will be enrolled in plans rated four stars or higher for 2027, against 20% for 2026 — a swing that goes most of the way to reversing the ratings collapse which has defined the equity story for two years. The shares closed on 9 October at USD 431.87, up 11.56% from USD 387.12, on roughly 5.0m shares against a recent average nearer 1.3m. Evercore ISI's Elizabeth Anderson put the resulting quality bonus at about USD 4.8bn. It lands in 2028, not 2027.

Which gives the honest shape of the answer to whether Humana is a good investment in 2026: the single largest swing factor in the thesis has moved decisively in the company's favour, and almost none of it reaches the income statement this year. In the same 9 October filing that disclosed the ratings, Humana affirmed guidance of at least USD 9.00 in adjusted (non-GAAP) EPS for 2026 — unchanged, because this year's earnings are still being set by the old ratings, through what the company calls the Bonus Year 2026 Star Ratings headwind. What has to go right from here is that the bonus arrives at something like the size analysts are modelling, and that it reaches shareholders rather than being recycled into richer member benefits to buy enrolment.

What actually happened

The Centers for Medicare and Medicaid Services published the 2027 Medicare Advantage and Part D Star Ratings on 8 October. Humana's own announcement put 95% of its Medicare Advantage membership in plans rated 4.0 stars or above. That is the company's figure, and it is worth being precise about it: independent analyses of the CMS data cluster slightly lower, with Stephens and a Healthcare Dive review of the raw files both arriving at 93%. The prior-year baseline is also read two ways — Humana and Becker's put 2026 at 20%, while the Healthcare Dive cut of the data has it at 41%, which reflects a different membership denominator rather than a different set of ratings.

Either pair tells the same story. Whether the move is 20% to 95% or 41% to 93%, Humana has gone from being the most conspicuous loser in the 2025 and 2026 ratings cycles to the clearest winner in this one, and it has done so by more than the sell side expected. J.P. Morgan had modelled 60% to 70% of members in four-star-plus plans. Oppenheimer's own estimate came in at about 95%, matching the company.

The mechanism matters more than the percentage. Star Ratings drive quality bonus payments, and those payments run on a two-year lag: the 2027 ratings set Bonus Year 2028 revenue. They also appear on the Medicare Plan Finder during open enrolment, which runs from 15 October to 7 December, so there is a second, faster channel — a four-star badge is a sales tool before it is a cheque. Humana had said ahead of the release that it would not comment on the Bonus Year 2028 implications until CMS published the final 2027 data, and its 9 October filing kept to that: it affirmed the 2026 adjusted EPS floor without putting a figure on the bonus.

Why the market reacted the way it did

An 11.6% single-day move on roughly four times normal volume is the market repricing a tail risk, not upgrading a forecast. For two years the bear case on Humana has not really been about medical cost trend, competition or the Medicare rate notice. It has been that a structurally impaired ratings book would keep compounding: low ratings cost bonus revenue, lost bonus revenue forces benefit cuts, benefit cuts lose members, and a shrinking membership makes the operational fixes harder to fund. That loop is what the 2027 ratings break.

The size of the move also says something about where the shares had got to. Humana trades well below its pre-downgrade levels, so a very large part of the quality-bonus recovery had been written out of the price entirely rather than discounted at some probability. When an outcome that had been treated as unlikely is confirmed, the repricing is abrupt — and that is the more useful way to read 9 October than as a judgement on 2028 earnings power.

Two caveats were doing the work on the other side of the trade, and both are legitimate. The first is timing: the money is a 2028 revenue event. Between now and then sit two annual rate notices, two bid cycles and a Q3 print. The second is Baird's point, which is the one that should sit at the front of any valuation work — a quality bonus is not free cash flow. It is revenue that managed care companies have historically competed away, pushing it back into supplemental benefits to win members during open enrolment. How much of USD 4.8bn survives to the bottom line is a management decision not yet taken, and not yet disclosed.

The Openbook read

This is where the ratings news changes the five-factor picture, and where it does not.

Momentum improves, but off a low base and from a damaged chart. One session of plus 11.6% on four times volume is a genuine break in trend rather than noise, and it comes with an identifiable catalyst rather than drifting higher on flow. What it does not do is repair two years of relative underperformance against the managed care group. Momentum scored on a three- or six-month lookback stays weak; on a one-month view it has turned.

Growth is the factor most directly re-rated, with a two-year delay attached. Quality bonus revenue is the highest-quality growth available to a Medicare Advantage carrier because it does not require winning a single new member. The 2027 ratings restore a line that had been removed from 2027 and 2028 forecasts. But Growth measured on trailing and current-year numbers does not move at all: 2026 adjusted EPS is still guided to decline year on year because of the Bonus Year 2026 headwind. The factor improves on a forward view and stays flat on a historic one.

Profitability is the factor to watch most carefully, and the one where labelling matters. Humana's affirmed adjusted EPS floor of USD 9.00 for 2026 is a non-GAAP figure. Its GAAP guidance is a materially different number and has moved separately — cut in the July release to at least USD 6.52 from at least USD 8.36, with the October filing flagging further potential change tied to value-creation and strategic initiatives. The gap between those two series is wide enough that comparing one year's adjusted figure with another year's reported figure would produce a thesis that is simply wrong. On either basis, the 2027 ratings do not improve 2026 margins; they improve the credibility of a 2028 margin recovery, and credibility is not yet margin.

Solvency is not really the contested factor here and does not move on this news. Humana's balance sheet was never the issue in the ratings episode — the risk was always to the earnings stream, not to the ability to fund it. What the ratings recovery does is reduce the probability of the scenario in which several years of depressed bonus revenue eventually forces a harder choice between benefit competitiveness and capital return. That is a reduction in tail risk rather than a change in leverage.

Reward/Risk is where the honest tension sits after an 11.6% day. The distribution has narrowed on the downside: the worst case, a second consecutive ratings failure, has been taken off the table for the 2028 bonus year, and that is a real improvement in the risk half of the ratio. The reward half is now partly spent. The question an investor has to answer is not whether USD 4.8bn is a large number — it is how much of a USD 4.8bn gross bonus converts to earnings after benefit reinvestment, and how much of that converted figure an 11.6% move has already paid for. Those are two separate unknowns stacked on each other, which is why the position is better described as improved than as cheap.

The read-across

Star Ratings are close to a zero-sum exercise in relative terms, and the 2027 cycle moved sharply against the rest of the group. UnitedHealth saw its share of Medicare Advantage members in four-star-plus plans fall to about 67% from 78%, though the company said the outcome was in line with its own expectations. Aetna, inside CVS Health, fell to 69% from 81%, and CMS also posted a low-performance warning against a California prescription drug plan operated by the unit. Elevance Health slipped to 45% from 53%, which desks read as a muted outcome given how low its starting point already was.

Industry-wide, 71% of Medicare Advantage enrollees are in plans rated at least four stars for 2027, and the number of plans achieving a full five stars fell to 15 from 22 for 2026. That combination — a tighter top end and a stable middle — is consistent with CMS continuing to make the measure set harder, which is the structural point for the whole sector rather than for Humana alone. A carrier that has just solved its ratings problem has solved it against a moving target, and the same methodology tightening that caught Humana in 2025 is now working against its larger rivals.

For anyone comparing the group on fundamentals rather than headlines, the Openbook screener is the place to put the managed care names side by side — the ratings divergence is about to show up as a divergence in 2028 revenue quality, not just in a week of share prices.

What to watch next

• Humana's own figure for the Bonus Year 2028 bonus. The company has still not quantified it, and the 9 October filing did not. That number is the next catalyst: the first company-sourced figure for the bonus, rather than a sell-side estimate.
• Open enrolment, 15 October to 7 December. The ratings go in front of beneficiaries. This is where a four-star badge either converts into membership growth or does not, and it is the cleanest early test of whether the ratings recovery is worth more than its bonus value.
• The Q3 print and the shape of 2027 guidance. The adjusted EPS floor of at least USD 9.00 for 2026 was described in the October filing as preliminary pending the third-quarter close. What matters more than the Q3 number is the first framing of 2027, the year that sits between the ratings win and the money.
• Benefit design for the 2028 plan year. The decision that determines how much of the bonus is retained will be visible in bid filings and benefit disclosures, not in a press release. Watch for management language about reinvestment versus margin recovery — that is the Baird question being answered.
• Whether rivals respond on price. With UnitedHealth, Aetna and Elevance all moving the wrong way on ratings, the competitive pressure may land on benefits across the industry. A general escalation in supplemental benefits would compress exactly the margin Humana is expected to recover.

Humana enters this week with the main structural objection to the equity partly withdrawn and a two-year wait before the cash appears. That is a different stock from the one that traded on 8 October, and a long way from a settled case.